journal
MENU ▼
Read by QxMD icon Read
search

Bone Marrow Transplantation

journal
https://www.readbyqxmd.com/read/28394371/stem-cell-transplantation-in-patients-with-systemic-al-amyloidosis-referred-for-transplant-after-suboptimal-responses-to-bortezomib-based-initial-therapy
#1
S W Wong, D Larivee, M Warner, K A Sprague, T Fogaren, R L Comenzo
No abstract text is available yet for this article.
April 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28394370/more-chronic-gvhd-and-non-relapse-mortality-after-peripheral-blood-stem-cell-compared-with-bone-marrow-in-hematopoietic-transplantation-for-paediatric-acute-lymphoblastic-leukemia-a-retrospective-study-on-behalf-of-the-ebmt-paediatric-diseases-working-party
#2
M Simonin, A Dalissier, M Labopin, A Willasch, M Zecca, A Mouhab, A Chybicka, A Balduzzi, L Volin, C Peters, P Bader, J-H Dalle
No abstract text is available yet for this article.
April 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28394369/revisiting-conditioning-dose-in-newly-diagnosed-light-chain-amyloidosis-undergoing-frontline-autologous-stem-cell-transplant-impact-on-response-and-survival
#3
N Tandon, E Muchtar, S Sidana, A Dispenzieri, M Q Lacy, D Dingli, F K Buadi, S R Hayman, R Chakraborty, W J Hogan, W Gonsalves, R Warsame, T V Kourelis, N Leung, P Kapoor, S K Kumar, M A Gertz
Autologous stem cell transplantation (ASCT) is an important treatment modality in light chain (AL) amyloidosis. Use of reduced-dose melphalan conditioning is common, given the associated organ and functional decline. The impact of full-intensity melphalan conditioning (n=314) was compared to reduced-dose conditioning (n=143). Patients in the full-intensity group were younger, with better performance status, fewer involved organs, lower tumor burden and lower Mayo stage. Full-dose conditioning was associated with higher rate of very good partial response or better (79% vs 62%; P<0...
April 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28394368/the-injured-heart-early-cardiac-effects-of-hematopoietic-stem-cell-transplantation-in-children-and-young-adults
#4
S J Rotz, T D Ryan, S Jodele, J L Jefferies, A Lane, A Pate, R Hirsch, J Hlavaty, A E Levesque, M D Taylor, M Cash, K C Myers, J A El-Bietar, S M Davies, C E Dandoy
We hypothesized that subclinical cardiac injury in the peri-transplant period is more frequent than currently appreciated in children and young adults. We performed echocardiographic screening on 227 consecutive patients prior to hematopoietic stem cell transplantation (HSCT), and 7, 30 and 100 days after transplant. We measured cardiac biomarkers cardiac troponin-I (cTn-I), and soluble suppressor of tumorigenicity 2 (sST2) prior to transplant, during conditioning, and days +7, +14, +28 and +49 in 26 patients...
April 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28394367/safety-of-pre-emptive-donor-lymphocyte-infusions-dli-based-on-mixed-chimerism-mc-in-peripheral-blood-or-bone-marrow-subsets-in-children-undergoing-hematopoietic-stem-cell-transplant-hsct-for-hematologic-malignancies
#5
https://www.readbyqxmd.com/read/28394366/nivolumab-salvage-therapy-before-or-after-allogeneic-stem-cell-transplantation-in-hodgkin-lymphoma
#6
J El Cheikh, R Massoud, I Abudalle, B Haffar, R Mahfouz, M A Kharfan-Dabaja, T Jisr, A Mougharbel, A Ibrahim, A Bazarbachi
No abstract text is available yet for this article.
April 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368382/second-degree-relative-donors-for-t-replete-haploidentical-allogeneic-stem-cell-transplantation-with-high-dose-post-transplant-cyclophosphamide-toward-crossing-the-major-hla-barrier
#7
A Garnier, T Guillaume, P Peterlin, M C Béné, Y Le Bris, V Dubruille, B Mahé, T Gastinne, C Touzeau, N Blin, S Le Gouill, P Moreau, P Chevallier
No abstract text is available yet for this article.
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368381/low-dose-5-azacytidine-as-preventive-therapy-for-relapse-of-aml-and-mds-following-allogeneic-hct
#8
J El-Cheikh, R Massoud, E Fares, N Kreidieh, R Mahfouz, M Charafeddine, M A Kharfan-Dabaja, A Bazarbachi
No abstract text is available yet for this article.
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368380/risk-of-melanocytic-nevi-and-nonmelanoma-skin-cancer-in-children-after-allogeneic-hematopoietic-stem-cell-transplantation
#9
J S Song, W B London, E B Hawryluk, D Guo, M Sridharan, D E Fisher, L E Lehmann, C N Duncan, J T Huang
There is a known increased risk of skin cancer in the adult population after hematopoietic stem cell transplantation (HSCT). However, late dermatologic effects that children may experience after HSCT have not been well described. The primary objective of this study was to characterize nevi and skin cancers affecting children after allogeneic HSCT. A cross-sectional cohort study of 85 pediatric HSCT recipients and 85 controls matched for age, sex and skin phototype was performed at a single institution. All participants underwent a full skin examination...
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368379/therapy-related-acute-myeloid-leukemia-and-myelodysplastic-syndrome-after-hematopoietic-cell-transplantation-for-lymphoma
#10
S Yamasaki, R Suzuki, K Hatano, K Fukushima, H Iida, S Morishima, Y Suehiro, T Fukuda, N Uchida, H Uchiyama, H Ikeda, A Yokota, K Tsukasaki, H Yamaguchi, J Kuroda, H Nakamae, Y Adachi, K-I Matsuoka, Y Nakamura, Y Atsuta, J Suzumiya
Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered...
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368378/sinusoidal-obstructive-syndrome-prophylaxis-with-recombinant-human-soluble-thrombomodulin-is-feasible-in-gemtuzumab-ozogamicin-treated-patients-undergoing-allogeneic-hematopoietic-cell-transplantation
#11
S Yamamoto, R Matsuno, Y Sugishita, R Kaneko, N Okamoto, M Koganesawa, S Fujita, K Akiyama, D Toyama, K Isoyama
No abstract text is available yet for this article.
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368377/prognostic-impact-of-the-european-leukemianet-standardized-reporting-system-in-older-aml-patients-receiving-stem-cell-transplantation-after-non-myeloablative-conditioning
#12
M Bill, M Jentzsch, J Grimm, K Schubert, T Lange, M Cross, G Behre, V Vucinic, W Pönisch, G-N Franke, D Niederwieser, S Schwind
No abstract text is available yet for this article.
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368376/predictors-of-overall-survival-among-patients-treated-with-sirolimus-tacrolimus-vs-methotrexate-tacrolimus-for-gvhd-prevention
#13
F Khimani, J Kim, L Chen, E Dean, V Rizk, B Betts, T Nishihori, F Locke, A Mishra, L Perez, E Ayala, M Kharfan-Dabaja, M Nieder, H Fernandez, C Anasetti, J Pidala
Sirolimus (SIR)/tacrolimus (TAC) is an alternative to methotrexate (MTX)/TAC. However, rational selection among these GvHD prophylaxis approaches to optimize survival of individual patients is not possible based on current evidence. We compared SIR/TAC (n=293) to MTX/TAC (n=414). The primary objective was to identify unique predictors of overall survival (OS). Secondary objective was to compare acute and chronic GvHD, relapse, non-relapse mortality, thrombotic microangiopathy (TMA), hepatic veno-occlusive disease (VOD/SOS), and acute kidney injury...
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368375/multiple-myeloma-patients-in-long-term-complete-response-after-autologous-stem-cell-transplantation-express-a-particular-immune-signature-with-potential-prognostic-implication
#14
A Arteche-López, A Kreutzman, A Alegre, P Sanz Martín, B Aguado, M González-Pardo, M Espiño, L M Villar, D García Belmonte, R de la Cámara, C Muñoz-Calleja
The proportion of multiple myeloma patients in long-term complete response (LTCR-MM) for more than 6 years after autologous stem cell transplantation (ASCT) is small. To evaluate whether this LTCR is associated with a particular immune signature, peripheral blood samples from 13 LTCR-MM after ASCT and healthy blood donors (HBD) were analysed. Subpopulations of T-cells (naïve, effector, central memory and regulatory), B-cells (naïve, marginal zone-like, class-switched memory, transitional and plasmablasts) and NK-cells expressing inhibitory and activating receptors were quantified by multiparametric flow cytometry (MFC)...
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368374/increase-of-bone-marrow-macrophages-and-cd8-t-lymphocytes-predict-graft-failure-after-allogeneic-bone-marrow-or-cord-blood-transplantation
#15
N Kawashima, S Terakura, S Nishiwaki, D Koyama, Y Ozawa, M Ito, K Miyamura
Graft failure (GF) remains an obstacle to survival after allogeneic hematopoietic stem cell transplantation. However, differentiating GF from delayed engraftment (DE) can be difficult. Host CD8(+) lymphocytes have been reported to mediate graft rejection, but the impact of macrophages on DE or GF is yet to be clarified. Peri-engraftment bone marrow (BM) specimens of 32 adult patients with normal engraftment, DE or GF were retrospectively evaluated to identify the potential associations of CD163(+) macrophage and CD8(+) lymphocyte infiltration into BM...
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28368373/is-myeloablative-dose-intensity-necessary-in-allogeneic-hematopoietic-cell-transplantation-for-lymphomas
#16
REVIEW
M A Kharfan-Dabaja, N El-Jurdi, E Ayala, A S Kanate, B N Savani, M Hamadani
The advent of novel immunotherapy and tyrosine kinase inhibitors has ushered a new era in the treatment of Hodgkin and non-Hodgkin lymphomas. Allogeneic hematopoietic cell transplantation remains, however, a vital component in the management and potential cure of lymphomas, especially in the relapsed setting. Considering the biological and clinical heterogeneity of various subtypes of lymphomas, the optimal intensity of conditioning regimens remains controversial. Reduced intensity conditioning regimens have broadened applicability of the procedure to older and frail patients...
April 3, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28346419/evolving-concepts-in-prognostic-scoring-of-chronic-gvhd
#17
REVIEW
A Lazaryan, M Arora
Chronic GvHD (cGvHD) remains one of the most complex and challenging complications after allogeneic hematopoietic cell transplantation. Emerging knowledge about the clinical manifestations and associated organ involvement of cGvHD has led to the establishment of prognostic parameters for post-transplant survival among affected allograft recipients. Studies employing the pre-National Institutes of Health (NIH) consensus data on cGvHD incidence and its risks have led to development of the CIBMTR's cGvHD risk stratification, which serves as the most refined and validated prognostic tool for estimating survival of patients with cGvHD...
March 27, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28346418/first-experience-of-hematopoietic-stem-cell-transplantation-treatment-of-shwachman-diamond-syndrome-using-unaffected-hla-matched-sibling-donor-produced-through-preimplantation-hla-typing
#18
A A Isaev, R V Deev, A Kuliev, I L Plaxa, N V Stancheva, A S Borovkova, I V Potapov, E A Pomerantseva, A G Chogovadze, K Y Boyarsky, A E Semenenko, A V Mikhailov, K G Shevchenko, A V Prikhodko, S Rechitsky, O V Paina, I M Barchatov, L S Zubarovskaya, O Verlinsky, I Y Bozo, B V Afanasyev
The only proven cure for Shwachman-Diamond syndrome (SDS) bone marrow failure is allogeneic hematopoietic stem cell transplantation (HSCT). However HSCT with donors other than HLA-identical siblings is associated with high mortality and unfavorable prognosis. This paper presents the first experience of HSCT treatment of SDS using an unaffected HLA-identical sibling produced through preimplantation genetic diagnosis (PGD). The patient was a 6-year-old blood transfusion-dependent SDS baby girl with secondary myelodysplastic syndrome, for whom no HLA-identical donor was available...
March 27, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28346417/bacterial-bloodstream-infections-in-the-allogeneic-hematopoietic-cell-transplant-patient-new-considerations-for-a-persistent-nemesis
#19
REVIEW
C E Dandoy, M I Ardura, G A Papanicolaou, J J Auletta
Bacterial bloodstream infections (BSI) cause significant transplant-related morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). This manuscript reviews the risk factors for and the bacterial pathogens causing BSIs in allo-HCT recipients in the contemporary transplant period. In addition, it offers insight into emerging resistant pathogens and reviews clinical management considerations to treat and strategies to prevent BSIs in allo-HCT patients.Bone Marrow Transplantation advance online publication, 27 March 2017; doi:10...
March 27, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28346416/jacie-accreditation-for-blood-and-marrow-transplantation-past-present-and-future-directions-of-an-international-model-for-healthcare-quality-improvement
#20
J A Snowden, E McGrath, R F Duarte, R Saccardi, K Orchard, N Worel, J Kuball, C Chabannon, M Mohty
Blood and marrow transplantation (BMT) is a complex and evolving medical speciality that makes substantial demands on healthcare resources. To meet a professional responsibility to both patients and public health services, the European Society for Blood and Marrow Transplantation (EBMT) initiated and developed the Joint Accreditation Committee of the International Society for Cellular Therapy and EBMT-better known by the acronym, JACIE. Since its inception, JACIE has performed over 530 voluntary accreditation inspections (62% first time; 38% reaccreditation) in 25 countries, representing 40% of transplant centres in Europe...
March 27, 2017: Bone Marrow Transplantation
journal
journal
20054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"